Replimune Historical Income Statement
| REPL Stock | USD 14.08 0.03 0.21% |
Historical analysis of Replimune income statement accounts such as Total Revenue of 0.0, Other Operating Expenses of 246.5 M, Research Development of 183.7 M or Cost Of Revenue of 2.2 M can show how well Replimune Group performed in making a profits. Evaluating Replimune income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Replimune's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Replimune Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Replimune Group is a good buy for the upcoming year.
Replimune |
About Replimune Income Statement Analysis
Replimune Group Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Replimune shareholders. The income statement also shows Replimune investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Replimune Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Replimune Group. It is also known as Replimune overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Replimune's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Replimune Group current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. At this time, Replimune's Total Other Income Expense Net is quite stable compared to the past year. Income Tax Expense is expected to rise to about 643.2 K this year, although the value of Depreciation And Amortization will most likely fall to about 2 M.
| 2023 | 2024 (projected) | Depreciation And Amortization | 2.7M | 2.0M | Interest Income | 580.8K | 935.8K |
Replimune income statement Correlations
Click cells to compare fundamentals
Replimune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Replimune income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | (1.9M) | (3.1M) | (2.2M) | (4.2M) | (6.7M) | (6.3M) | |
| Depreciation And Amortization | 533K | 4.1M | 4.6M | 2.4M | 2.7M | 2.0M | |
| Interest Expense | 1.9M | 3.1M | 2.2M | 4.2M | 2.2M | 1.9M | |
| Selling General Administrative | 17.4M | 23.2M | 38.8M | 50.6M | 59.8M | 62.8M | |
| Gross Profit | (1.8M) | (4.1M) | (4.6M) | (2.4M) | (2.7M) | (2.8M) | |
| Other Operating Expenses | 53.1M | 77.1M | 115.1M | 174.2M | 234.8M | 246.5M | |
| Operating Income | (56.2M) | (80.0M) | (118.3M) | (177.1M) | (234.8M) | (223.0M) | |
| Net Income From Continuing Ops | (52.6M) | (80.9M) | (118.0M) | (174.3M) | (215.8M) | (205.0M) | |
| Ebit | (53.1M) | (80.6M) | (119.0M) | (172.8M) | (232.9M) | (221.2M) | |
| Research Development | 38.8M | 56.8M | 79.5M | 126.5M | 175.0M | 183.7M | |
| Ebitda | (52.6M) | (76.5M) | (114.4M) | (170.3M) | (230.2M) | (218.7M) | |
| Cost Of Revenue | 1.8M | 4.1M | 4.6M | 2.4M | 2.7M | 2.2M | |
| Total Operating Expenses | 53.1M | 77.1M | 115.1M | 174.2M | 234.8M | 246.5M | |
| Income Before Tax | (52.6M) | (80.9M) | (118.0M) | (174.0M) | (215.4M) | (204.6M) | |
| Total Other Income Expense Net | 2.4M | (915K) | 278K | 3.1M | 19.4M | 20.4M | |
| Net Income Applicable To Common Shares | (30.8M) | (52.6M) | (80.9M) | (118.0M) | (106.2M) | (100.9M) | |
| Net Income | (52.6M) | (80.9M) | (118.0M) | (174.3M) | (215.8M) | (205.0M) | |
| Income Tax Expense | 1.9M | 2.4M | 1.2M | 288K | 408K | 643.2K | |
| Reconciled Depreciation | 533K | 1.7M | 2.1M | 2.4M | 2.7M | 1.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.